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Abstract
Summary Using a large cohort of hip fracture patients, we
estimated hospital costs to be £14,163 and £2139 in the first
and second year following fracture, respectively. Second hip
and non-hip fractures were major cost drivers. There is a
strong economic incentive to identify cost-effective ap-
proaches for hip fracture prevention.
Introduction The purpose of this study was to estimate hospi-
tal costs of hip fracture up to 2 years post-fracture and com-
pare costs before and after the index fracture.
Methods A cohort of patients aged over 60 years admitted
with a hip fracture in a UK region between 2003 and 2013
were identified from hospital records and followed until death
or administrative censoring. All hospital records were valued
using 2012/2013 unit costs, and non-parametric censoring
methods were used to adjust for censoring when estimating
average annual costs. A generalised linear model examined
the main predictors of hospital costs.
Results A cohort of 33,152 patients with a hip fracture was
identified (mean age 83 years (SD 8.2). The mean censor-
adjusted 1- and 2-year hospital costs after index hip fracture
were £14,163 (95 % confidence interval (CI) £14,008 to £14,
317) and £16,302 (95 % CI £16,097 to £16,515), respectively.
Index admission accounted for 61 % (£8613; 95 % CI £8565
to £8661) of total 1-year hospital costs which were £10,964
higher compared to the year pre-event (p<0.001). The main
predictors of 1-year hospital costs were second hip fracture,
other non-hip fragility fractures requiring hospitalisation and
hip fracture-related complications. Total UK annual hospital
costs associated with incident hip fractures were estimated at
£1.1 billion.
Conclusions Hospital costs following hip fracture are high
and mostly occur in the first year after the index hip fracture.
Experiencing a second hip fracture after the index fracture
accounted for much of the increase in costs. There is a strong
economic incentive to prioritise research funds towards iden-
tifying the best approaches to prevent both index and subse-
quent hip fractures.
Keywords Burden . Cost . Epidemiology . Health
economics . Hip fracture . Osteoporosis
Introduction
Hip fractures are a major public health problem in terms of
patient morbidity, mortality and costs to health and social care.
The incidence of hip fracture increases steeply with age due to
higher rates of osteoporosis and falls in the elderly population.
Hip fractures account for the majority of osteoporotic fragility
fractures and for over 40 % of the estimated burden of osteo-
porosis worldwide [1]. In 2010, there were an estimated 600,
000 incident hip fractures in the European Union, costing €20
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billion and accounting for 54 % of the total costs of osteopo-
rosis [2]. In the UK, the annual number of hip fractures is
expected to increase from 79,000 to 104,000 by 2025 [2].
Existing estimates of the health and social care costs of hip
fractures in the UK range from £2 billion to £3 billion [2, 3],
but these were based on UK cost data that are over 10 years
old [2, 4, 5].
It is important to have robust and up-to-date evidence of the
economic impact of hip fracture and its main drivers. Such
data are essential to inform decisions about changes in health
service delivery aimed at achieving greater efficiency and bet-
ter patient care. Furthermore, such information is key to in-
vestment and disinvestment decisions regarding new osteopo-
rosis and hip fracture prevention interventions as these are
driven by cost-effectiveness analysis [6], where a key input
is the long-term cost of hip fracture.
The primary aim of this study is to estimate the hospital
costs of hip fracture up to 2 years post event for both index
fracture and subsequent fracture, using a large patient-level
dataset representative of the UK hip fracture population. Sec-
ondly, we compare hospital costs before and after the event to
explore the impact of significant co-morbidities in individuals
with hip fracture. Finally, we report the main predictors of
hospital costs following hip fracture.
Methods
Setting and data sources
This study adopted an incidence-based approach to estimate the
secondary care costs associated with hip fracture. Data were
obtained from the Hospital Episode Statistics (HES) database
for a representative region of the UK covering a population of
around 4 million people and with 11 National Health Service
(NHS) hospitals treating fragility fractures [7]. This database
captures all hospital NHS patient care, as well as private pa-
tients treated in NHS hospitals and care delivered by treatment
centres (including private providers) funded by the NHS. It
contains anonymised patient administrative information (such
as date of admission and discharge, admission method, age,
gender and length of stay), diagnosis (ICD-10) and procedures
codes (OPCS-4). We extracted inpatient care data from April
1999 to March 2013, hospital outpatient activity from April
2003 and accident and emergency attendances from April
2007. Deaths were obtained from the linked HES and the Of-
fice of National Statistics (ONS) mortality database, which
captures deaths occurring in and out of hospital.
Study participants
We identified HES records for all patients over 60 years of age
who had had an emergency hospital admission with a primary
ICD-10 diagnosis code for hip fracture (S72.0, S72.1, S72.2,
S72.9) between April 2003 and March 2013. We extracted all
HES records before and after that admission. A number of
exclusion criteria were applied to minimise misclassification:
(1) day cases were excluded by imposing a condition that
patients had to stay at least one night in hospital, unless death
occurred in the first 24 h of admission; (2) individuals who
had had a previous hip fracture between April 1999 and
March 2003 were excluded to reduce duplicate coding of
hip fractures that occurred before the period of analysis but
led to repeat hospital admissions due to complications or un-
resolved sequelae; and (3) patients were also excluded if they
had had a hip fracture due to trauma, such as transport acci-
dents using ICD-10 codes (V01–V99).
When estimating hospital costs in the year before and after
fracture, we included only patients with an index admission
after 1 April 2008, to ensure that outpatient and emergency
attendances costs would be included. We refer to this set of
results as ‘total hospital’ costs and contacts. Conversely, we
used the whole HES dataset (April 2003 to April 2013) to
report costs due to hospitalisation, critical care and day cases,
and benefit from the increased statistical power. We refer to
these results as ‘hospitalisation’ costs.
Ascertainment of subsequent fracture/s
Subsequent hip fracture/s were identified using the same ap-
proach as for the index fracture. However, to ensure this was a
separate fracture and not hospital re-admissions due to adverse
effects of the index fracture, we counted second hip fractures
only if admitted in a separate ‘continuous inpatient spell’
(CIPS) from index admission and at least 30 days after admis-
sion for the primary fracture. A CIPS is made up of one or more
hospital spells (i.e. time patient stays in one hospital) and is
defined as a continuous period of care within the NHS, regard-
less of any transfers to another hospital. A hospital spell starts
with the index admission, involves treatment by one or more
consultants (i.e. finished consultant episodes—FCE) and ends
when the patient dies or is discharged from hospital [8].
Ascertainment of surgery and mortality
All-cause mortality was estimated at 30 days and 1 year from
the day of emergency admission due to hip fracture and using
the date of death from the ONS mortality database. We also
ascertained whether patients were recorded as having surgery
during the initial hospital spell following hip fracture. Surgery
was identified using OPCS-4 codes for fixation (W19, W20,
W22, W24 and W25 covering open or close reduction and
internal or external fixation), prosthetic replacement of the
head of the femur (W46, W47, W48) and total hip replace-
ment (W37,W38,W39,W93,W94,W95). We also examined
the side of the first and subsequent hip fractures managed with
550 Osteoporos Int (2016) 27:549–558
surgery using OPCS-4 codes (Z941 for bilateral operation,
Z942 for right-side operation and Z943 for left-side
operation).
Costs
Each finished consultant episode (FCE) in a hospital spell was
assigned into a Healthcare Resource Group (HRG) via the
2012/13 Casemix Grouper Software (HRG4+) [9]. HRGs
are standard groups of clinically similar treatments that con-
sume a common set of healthcare resources. We did not sep-
arate acute care from rehabilitation admission as, in the UK,
rehabilitation generally starts following acute care in the gen-
eral ward, in which patients may stay for weeks or be admitted
later into specialist rehabilitation wards or community hospi-
tals. All resource use was valued using 2012–2013 prices that
were obtained from the schedule of reference costs for NHS
trusts [10]. The costs for inpatient stay and outpatient visits
include the costs of treatment and diagnostic interventions.
Total costs per patient were aggregated into monthly and an-
nual amounts for the purposes of the analysis.
Statistical analysis
The HES database was censored in March 31, 2013, and com-
plete follow-up was not available for all cases. Hence, we report
total hospital costs for those patients with complete follow-up
data at years 1 and 2 following hip fracture and for the whole
sample after adjusting for censoring using the methodology de-
veloped by Lin et al. [11]. This involved dividing the study
period into days and estimating the mean daily costs across all
patients who are alive at the beginning of a given day, i.e. com-
plete cases. The mean daily costs were then multiplied by the
Kaplan-Meier survival probability of being alive at the beginning
of each day and summed over the entire period of interest (i.e. 1
and 2 years) to obtain the mean censor-adjusted costs. Costs are
reported as means together with their 95 % confidence intervals
(CIs), obtained from 1000 bootstrap estimates.
We determined the marginal costs from hip fracture by com-
paring costs in the year before and after the index hip fracture.
The national total annual hospital costs of hip fracture were
determined by multiplying the incidence of hip fracture in the
UK (79,243 in 2010) by the estimated costs per hip fracture [2].
Predictors of hospitalisation costs of hip fracture were estimat-
ed using a generalised linear model (GLM). After reviewing the
literature, we examined the following predictors of costs in the
year of the hip fracture: age at fracture; type of fracture (head and
neck: S72.0; pertrochanteric: S72.1; subtrochanteric: S72.2; un-
specified: S72.9); gender; Charlson co-morbidity score (compli-
cations at fracture and occurring up to 3 years before fracture)
[12]; place of residence pre- and post-fracture (own home or care
home: residential or nursing home); occurrence of second hip
fracture; history of other osteoporotic major fragility fractures
requiring hospitalisation pre- and post hip fracture (spine, wrist,
pelvis, rib, humerus and other identified with ICD-10 diagnosis
codes: S22, S32, S42, S52.0-S52.3, S22.5 and S22.6); primary
hip replacement and revision [13]; complications of internal or-
thopaedic devices (ICD-10 code: T84) and infection or haemor-
rhage following procedure (T81.0 and T81.4); dislocation
(M24.3 and M24.4); malunion and non-union of fracture
(M84.0–M84.2); periprosthetic fracture (M96.6); other/
unspecified postprocedural musculoskeletal disorders (M96.8,
M96.9); sequelae of fractures of the femur (T93.1); hip luxations
(S73.0); ethnicity (white and non-white); year of hip fracture; all-
cause mortality within 30 days and between days 31 days and
1 year; and income deprivation measured by the index of multi-
ple deprivation. The choice of the GLM model family and link
functions was informed by the modified Park test and the Box-
Cox test, respectively. Model fit was assessed using Pregibon’s
Link test, and different family and link functions were compared
using Akaike’s information criterion. Univariate analyses in con-
tinuous variableswere performed using Student t tests. Avariable
was deemed to be statistically significant if p<0.01 to account for
the large sample size, and 95% CI were reported for ease of
comparison with other studies. All analyses were performed
using STATAversion 12 (StataCorp, College Station, TX).
Results
Patient sample
Between April 1, 2003, and March 31, 2013, 33,152 patients
were identified as having had a hip fracture. Mean age of the
sample was 83 years (SD 8.2) and 75 % were female. The
majority of the population was of white ethnicity. Baseline
characteristics of the study participants are shown in Table 1.
Women were older than men (+2.0 years) and less likely to
have a history of complications (CCI score of 1.1 vs. 1.7 in
men) at index hip fracture.
Patient outcomes and hospitalisation costs
The average follow-up of the cohort was 2.6 years (median
1.8 years; SD 2.5; range 0–10 years) from index hip fracture,
during which time 6.6 % of patients suffered a second hip
fracture (Table 2). The proportion of patients recorded as re-
ceiving hip surgery was 93.1 % (n=30,858) and 90 % (n=
1987) at index and second hip fracture, respectively. Of pa-
tients with a second hip fracture, 83.3 % (n=1837) had both
surgery and side of surgery recorded at the first and second hip
fracture. Only 6.3 % (n=1721) of these subset of patients were
recorded as having a second hip fracture on the same side as
the index fracture. In terms of the initial hospital admission, no
significant difference was found in length of stay between
patients with a second hip fracture on the same side of the
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index fracture and those with a fracture on the opposite side
(2.8 additional days, 95 % CI −0.7 to 6.2 days).
Mortality at 30 days and 1 year following index fracture was
estimated to be 9.4 and 31.2 %, respectively. Within 30 days of
the index fracture, the age-standardised proportion of patients
who died was 14.2 % amongst male patients and 7.9 %
amongst female patients (using the direct standardisation meth-
od and the age distribution of the whole hip fracture sample).
Within 1 year of the index fracture, the age-standardised mor-
tality amongst male and female patients was estimated to be
42.3 and 27.5%, respectively. After index fracture, themajority
of patients were recorded as being discharged to their own
home (49 %), or transferred to another hospital (23 %) or to a
care home (18 %). Ten percent of patients died in hospital
during the index admission. The number of patients in a care
home increased to 24 % after 1 year of complete follow-up. In
contrast, after a second hip fracture, 32 % of patients were
Table 1 Patient characteristics at index hip fracture
Age, mean (SD) 82.7 (8.2)
Type of hip fracture, n (%)
Fracture of head and neck of femur (S72.0) 25,335 (76.4 %)
Pertrochanteric fracture (S72.1) 6590 (19.9 %)
Subtrochanteric fracture (S72.2) 913 (2.8 %)
Unspecified fracture of femur (S72.9) 315 (1.0 %)
Males, n (%) 8355 (25.2 %)
White ethnicitya 31,287 (98.9 %)
Index of multiple deprivation (IMD) score
Multiple deprivation, mean (SD)b 13.4 (10.4)
Income deprivation, mean (SD)c 0.094 (0.0729)
Mean Charlson co-morbidity index, mean (SD) 1.26 (1.57)
Median (interquartile range) 1 (0–2)
Score 0–2, n (%) 27,379 (82.6 %)
Score 3–4, n (%) 4071 (12.3)
Score 5 or higher, n (%) 1702 (5.1 %)
History of complications recorded in
previous hospitalisations, n (%)
Dementia 6101 (18.4 %)
Pulmonary disease 4594 (13.9 %)
Diabetes 3841 (11.6 %)
Stroke 3163 (9.5 %)
Myocardial infarction 3068 (9.3 %)
Cancer 2895 (8.7 %)
Source of admission at index fracture, n (%)
Own home 27,985 (84.4 %)
Nursing/residential/temporary accommodation 3681 (11.1 %)
Another hospital 1415 (4.4 %)
Unknown 35 (0.1 %)
a 1504 missing
b 183 missing
c 172 missing
Table 2 Patient outcomes and hospitalisation costs after index hip fracture
Follow-up time in years, mean (SD) 2.6 (2.5)
Second hip fracture, n (%) 2206 (6.6 %)
Time to second hip fracture in years, mean (SD) 2.2 (2.0)
Surgery or implant-related complicationsa, n (%)
Within index fracture hospital 1015 (3.1 %)
Within 1 year of fractureb 1942 (6.4 %)
Hip replacement surgeryc, n (%)
Within index fracture hospitalisation 1522 (5.0 %)
Within 1 year of fractureb 1781 (5.9 %)
Hip revision surgeryc, n (%)
Within index fracture admission 247 (0.7 %)
Within 1 year of fractureb 463 (1.5 %)
Mortality, n (%)
Within 30 daysd 3101 (9.4 %)
Within 1 yearb 9492 (31.2 %)
Discharge destination following index
fracture admission, n (%)
Own home 16,126 (48.6 %)
Care home or temporary accommodation 5957 (18.0 %)
NHS hospital 7453 (22.5 %)
Unknown 371 (1.1 %)
Dead 3245 (9.8 %)
Living in a care home within 1 year of
index fractureb
7409 (24.4 %)
Newly transferred to a care home within
1 year of index fractureb (living in different
setting prior to hip fracture)
4912 (16.1 %)
Total length of hospital stay within 1 year of
fractureb, mean (SD)
Initial hospitalisation 20.5 (20.0)
Emergency hospitalisations after discharge 6.9 (19.0)
Non-emergency hospitalisations after discharge 11.3 (28.6)
Total 38.6 (41.2)
Hospital inpatient re-admissions within 1 year
of fractureb
Emergency, mean (SD) 0.5 (0.9)
Non-emergency, mean (SD) 0.4 (0.9)
Total, mean (SD) 0.9 (1.4)
Initial hospitalisation costs (index admission
to discharge)
Primary hip fracture, mean (SD) £8663 (4605)
Second hip fracture, mean (SD) £8544 (4178)
Hospitalisation costs within 1 year of fractureb
Emergency-related costs, mean (SD) £10,854 (7268)
Non-emergency-related costs, mean (SD) £2972 (7896)
Total, mean (SD) £13,826 11,016
Hip fracture-related hospitalisation costs
within 1 year of admissionb, mean (SD)
£10,375 (6962)
a ICD-10 codes T81.0, T81.4 and T84
b Cases with complete follow-up, including those who died in that year
(n=30,430)
c Using OPCS codes defined by the National Joint Registry [13]
d Cases with complete follow-up during the 30 days (n=32,989)
552 Osteoporos Int (2016) 27:549–558
discharged to a care home after hospital discharge, which in-
creased to 40 % amongst patients with at least 1 year of follow-
up. Hospital re-admissions for any reason with inpatient stay in
the year following the index hip fracture totalled 0.9 (median 0,
SD 1.4, IQR 0–19) per patient or 1.8 (median 1, SD 1.6, IQR
1–19) per patient re-admitted. Of these re-admissions, 57 %
were emergency admissions and accounted for 18.1 (median
0, SD 35.9, IQR 0–22) additional days in hospital per patient or
37.2 (median 23, SD 43.9, IQR 8–50) additional days per pa-
tient re-admitted. About 50 % of diagnosis codes in non-
emergency inpatient admissions following index admission
were hip fracture related.
The hospitalisation costs associated with index admission for
primary hip fracture were £8663 (median £8049, SD 4605) com-
pared to £8544 (median £8049, SD 4112) for the second hip
fracture. Length of stay in the index admission was 20.5 (median
14, SD 20.0, IQR 9–307) and 20.8 (median 15, SD 18.8, IQR 9–
139)days for primary and second hip fracture, respectively. For
patients suffering a subsequent hip fracture (6.6 %), the hospital
admission following the second hip fracture resulted in signifi-
cantly higher length of stay (2.0 days, p<0.001, 18.8 vs.
20.8 days) and costs (£406, p<0.001, £8138 vs. £8544) relative
to the index fracture. Within the first year following primary hip
fracture, the total hospitalisation costs were estimated to be £13,
826 (median £10,425, SD 11,016), of which 75 % were due to
hip fracture-related admissions (£10,375, median £8050).
Hospitalisation costs and length of stay were highly correlated
(Spearman correlation coefficient 0.82, p<0.001).
Figure 1 reports the hospitalisation costs in the months
before and after primary hip fracture. The annual cost in the
year of the fracture was estimated to be £10,860 (95%CI £10,
710 to £11,011) higher compared to that of the previous year.
The highest costs occur in the first 6 months post hip fracture,
dropping sharply afterwards to pre-fracture levels of expendi-
ture and remaining fairly constant throughout the second year
post-fracture. The 2-year survivors show a similar pattern of
costs relative to all patients. However, while the costs in the
second year after hip fracture remain numerically higher than
in the year pre-fracture (£112, 95%CI −£29 to £274), this was
not statistically significant.
Total hospital costs before and after index fracture
Forty-four percent (n=14,552) of patients had a primary hip
fracture after 1 April 2008 and complete 1-year follow-up.
They were used to compare hospital resource use and total
costs in the years before and after the fracture (Table 3). In
the year following hip fracture, patients had 1.03 additional
hospital admissions (i.e. inpatient stay, day cases and regular
day/night attenders) (p<0.001), 27.9 additional hospital inpa-
tient days (p<0.001), 0.54 additional accident and emergency
contacts (p<0.001) and 0.01 additional outpatient visits
(p<0.001) compared with the previous year.
Including both outpatient and emergency contacts, the total
costs were estimated at £14,264 in the year of the fracture, of
which 96 % (£13,635) were due to inpatient stay and critical
care. Unadjusted for other covariates, men had significantly
higher total hospital costs compared to women (£1188,
p<0.001). Having a hip fracture resulted in additional costs
of £10,964 (95 %CI £10,767 to £11,161) compared to the year
prior to hip fracture. Adjusting for censoring, the 1-year costs
were similar to the complete-case analysis at £14,163 (95 % CI
£14,008 to £14,317). The costs in the first 2 years following hip
fracture (2-year) adjusted for censoring were £16,302 (95 % CI
£16,097 to £16,515) compared to £16,270 using only the com-
plete cases (n=12,155). Conditional on surviving the year fol-
lowing hip fracture, hospital costs were £3072 in the second
year using only the complete cases (n=7624).
Annual hospital cost of hip fractures in the UK
The total annual hospital costs associated with all incident hip
fractures in the UK amongst those aged 50 (n=79,243) were
estimated at £1130 million. Considering only the costs attrib-
utable to hip fracture (marginal), hip fracture was estimated to
cost £869 million per year (Table 4).
Predictors of hospitalisation costs in the first year
following hip fracture
The predictors of hospitalisation costs are shown in Table 5. A
GLM model with gamma family and identify link function
had the best fit. Adjusting for all covariates, men had higher
hospitalisation costs than women (£910, 95 % CI £679 to
£1141) and higher length of stay (4.5 days). Furthermore,
costs were positively associated with age (£45 per additional
year) and inversely associated with income, with costs rising
with income deprivation. A higher Charlson co-morbidity
score at index hip fracture increased hospitalisation costs by
approximately £694 per additional unit of the Charlson score.
Transiting to a care home for the first time after index fracture
was associated with higher hospital costs (£5583; 95 % CI
£5197 to £5970) and a longer length of stay (22 days) relative
to patients who went back to their previous accommodation,
possibly indicating poorer health.
Holding all else constant, having a second hip fracture within
the same year as the primary one was associated with an addi-
tional £9198 (95 % CI £8059 to £10,337) expenditure in
hospitalisation costs.Major (non-hip) fragility fractures requiring
hospitalisation post hip fracture were also found to be signifi-
cantly associated with higher hospitalisation costs (£5705,
95 %CI: £4434 to £6975). Amongst hip fracture-related compli-
cations, surgical complications within and after index admission
were the most frequently reported and were associated with
higher costs and length of stay (22 and 25 days, respectively)
relative to no complications. Periprosthetic fracture was also
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associated with significantly higher hospitalisation costs relative
to patients without this, at £9569 (95 % CI £6302 to £12,835).
Finally, patients who died within 30 days were associ-
ated with lower hospitalisation costs (−£4672; 95 % CI −
£4906 to −£4437), mostly as a result of lower length of
stay than those who survived the first 30 days (mean of
11.3 vs. 41.9 days). Patients who died after 30 days had
higher costs (£2549; 95 % CI £2246 to £2853) than the
survivors, again mostly due to a longer length of stay
(mean of 53.2 days vs. 38.3 days).
Discussion
In this study, we estimated the immediate- and medium-term
(up to 2 years) hospital costs of hip fracture in a large repre-
sentative sample of patients in the UK, adjusted for hospital
use prior to the index fracture, explored the main variables
influencing these costs, and estimated the attributable costs
of all hip fractures in the UK. We also identified the second
hip fracture within the first year of index fracture as a major
predictor of additional cost.
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Table 3 Resource use and costs in the year prior to and after hip fracture (April 2008–May 2013)
Total A&E Outpatient care Inpatient care Length of
stay
Sample
size
Resource use, annual
Before index fracture – 0.71 3.10 1.20 8.29 14,552
After, complete casesa – 1.26 3.13 2.23 36.14 14,552
Difference, after vs. before – 0.54** 0.03** 1.03** 27.85**
Hospital costs, annual
Before index fracture £3299 £105 £295 £2899 – 14,552
After, complete casesa £14,264 £202 £297 £13,765 – 14,552
Difference, after vs. before £10,964** (10,767 to 11,161) £96** (93 to 101) £2 (−9 to 12) £10,865** (10,671 to 11,060) –
After, censor-adjusted £14,163 (14,008 to 14,317) £207 (204 to 210) £303 (293–313) £13,653 (13,501 to 13,812) – 17,274
a Complete cases including those who died in given year
**p<0.001
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Table 4 Total annual hospital
costs associated with hip fractures
in the UK
Absolutea Marginalb
Annual incident hip fractures in the UK 79,243 79,243
Accident and emergency cost per hip fracture, £ £202 £96
Outpatient cost per hip fracture, £ £297 £2
Hospitalisation cost per hip fracture, £ £13,765 £10,865
Annual total hospital cost per incident hip fracture, £ £14,264 £10,964
Total cost, £ million £1130 £869
aAbsolute denotes 1-year costs following hip fracture
bMarginal denotes the difference in 1-year costs relative to the year before the hip fracture
Table 5 Predictors of 1-
year hospitalisation costs
after index hip fracture
Frequency Mean Low 95 %CI High 95 %CI p>z
Type of hip fracture
Head and neck 76.9 % Reference
Pertrochanteric 19.4 % −£266 −£505 −£28 0.029
Subtrochanteric 2.7 % £491 −£137 £1119 0.125
Unspecified 1.0 % £610 −£432 £1653 0.251
Gender
Female 74.8 % Reference
Male 25.2 % £910 £679 £1141 <0.001
Age at hip fracture (centred on 82 years) £47 £35 £60 <0.001
Year at hip fracture (centred on year 2008) −£99 −£135 −£63 <0.001
Indices of income deprivation (×100) £31 £18 £45 <0.001
Charlson co-morbidity score
(up to 3 years prior fracture)
£695 £622 £768 <0.001
Death within 30 days of hip fracture 10.2 % −£4672 −£4906 −£4437 <0.001
Death between 31 days and 1 year 21.5 % £2549 £2246 £2853 <0.001
Living in care home before hip fracture 9.6 % −£595 −£896 −£294 <0.001
Moving to care home after hip fracture (new) 16.1 % £5583 £5197 £5970 <0.001
Second hip fracture 2.7 % £9198 £8059 £10,337 <0.001
Major fragility fracture requiring
hospitalisation post hip fracture
1.5 % £5705 £4434 £6975 <0.001
Surgical complications within index
admissiona
3.1 % £5694 £4849 £6538 <0.001
Surgical complications after discharge
from index admissiona
3.3 % £10,552 £10,352 £10,753 <0.001
Malunion and non-union of fractureb 0.5 % £4613 £2396 £6830 <0.001
Periprosthetic fracturec 0.3 % £9569 £6302 £12,835 <0.001
Hip luxationsd 0.1 % £14,266 £7630 £20,902 <0.001
Sequelae of fractures of the femure 0.2 % £8463 £3545 £13,381 <0.001
Constant £10,551 £10,351 £10,753 <0.001
No. of observations 30,282
Residual degrees of freedom 30,261
Link test (p value for yhat square) 0.41
AIC 20.98
a ICD 10 codes T81.0, T81.4 and T84
b ICD 10 codes M84.9–M84.2
c ICD 10 code M96.6
d ICD 10 code S73.0
e ICD 10 code T93.1
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Although previous studies have reported costs of hip frac-
ture in the UK, few were based on patient-level data or on
recent populations. Moreover, previous cost estimates have
been mostly informed by studies using small sample sizes
(between 10 [14] and 2427 patients [15]), and using a variety
of time horizons from initial discharge following acute admis-
sion [16–19] up to 12 months post admission [14, 15]. When
the results of these previous studies were inflated to 2012/
2013 prices, we also found considerable heterogeneity across
them, with estimates of hospitalisation costs ranging from
£5083 [15] to £16,452 [17]. Wide variability was also present
in the reported 1-year costs after hip fracture, with estimates
between £6176 [15] and £20,470 [14] in studies focusing only
on women with hip fractures. Also, one study estimated the
marginal 1-year costs to be £4222 higher per women with hip
fracture compared to women without hip fracture [15] which
is considerably lower than what we found in our study. In
contrast, a recent UK study, based on 8208 patients, estimated
the index hospitalisation cost of a hip fracture to be similar to
our estimates (£8330) [20] and the 1-year costs to be £12,475
higher compared to the year pre-fracture, which is slightly
higher than our estimate (£10,860). However, the sample used
in this study was younger than the typical UK hip fracture
population, with the broader inclusion criteria (ICD-10:
S72.0–S72.9 and M84.4, all ages, all admissions) resulting
in a patient sample with a lower age at admission (mean
79 years) compared to our cohort (83 years) and the UK hip
fracture audit data [21]. Furthermore, the proportion of pa-
tients with dementia at index fracture was considerably lower
than in our cohort (12 vs. 18 %), suggesting that patients
admitted from a care home may have been unrepresented,
which may also explain the small proportion of patients being
discharged to a care home following hip fracture (4.4 % vs.
18.0 % in our study) [20]. Hence, our study contributes sig-
nificantly to the evidence base regarding hip fractures by iden-
tifying and following a population of 33,172 patients with hip
fractures up to 2 years before and after the index event.
We found the hospital costs to be high in the first 6 months
after hip fracture, falling thereafter to levels of expenditure
similar to the year before fracture. The same cost profile was
observed in patients with a second hip fracture; however, ini-
tial admission costs were higher in the second fracture com-
pared to the first. Acute hospitalisation costs due to index
fracture accounted for 61 % (£8663) of total 1-year costs
and these costs were similar between first and second hip
fracture, representing about 20 days of inpatient stay. Hospital
costs in the year following hip fracture were estimated to be
£14,264, representing 36 days of inpatient stay, with the ma-
jority of costs being associated with hip fracture-related
hospitalisations (75 %). Furthermore, the 2-year costs at
£16,289 show that the majority of costs (88 %) occur in the
year after the index hip fracture. Comparing costs before and
after hip fracture showed these to gradually increase in the last
6 months prior to fracture, suggesting a worsening in health
that may be associated with the risk of fracture. Such a pattern
in costs is consistent with what has been reported in diseases
such as stroke [22]. Also, men incurred higher hospital costs
following a hip fracture compared to women, even after
adjusting for several covariates. This is of concern as men
are more likely to be underdiagnosed and have lower treat-
ment uptake rates for osteoporosis before and after a fragility
fracture compared to women [23].
Using the annual number of incident hip fracture cases, we
were able to extrapolate our findings to the UK as a whole and
estimate the cost to the hospital services in the year of the
fracture. This was estimated to be £1131 million a year, and
if incidence is to rise by 32 % in 2025 [2], the hospital costs
within the year of the fracture will increase to £1493 million a
year. Furthermore, given the high marginal annual costs of hip
fracture per patient (£10,964), there is a considerable econom-
ic incentive to fund research aimed at identifying cost-
effective ways of improving the uptake of osteoporosis thera-
pies and the implementation of embedded care pathways
across healthcare services to effectively reduce avoidable frac-
tures. Such data would aid decision makers implement policy
decisions at a local and national level. A potential cost-
effective approach is through the implementation of coordi-
nated approaches to fracture prevention such as fracture liai-
son services (FLS) [23, 24]. The Glasgow Fracture Liaison
Service [25] reported that for every 1000 patients with a fra-
gility fracture assessed by FLS, 18 fragility fractures (includ-
ing 11 hip fractures) were prevented. This equates to potential
savings of £120,604 per 1000 patients from the hip fractures
averted alone. However, the savings could be potentially
higher, as non-hip fractures, given their higher frequency, lead
to greater health resource utilisation as measured by days of
hospitalisation (2.9 times greater), community rehabilitation
and nursing home care than hip fractures [26]. Another major
consequence of fragility fractures is the consequent increases
in non-health care costs, resulting from the use of social care
services, admission to care homes, and provision of unpaid
care by friends and relatives [27]. Further research is needed to
determine these costs for both hip and non-hip fragility
fractures.
The main predictors of first year costs were found to be
mostly events related with hip fracture. Having a second hip
fracture in the same year as the index fracture was associated
with higher costs (£9198). A major focus for preventative
therapy is targeted use of osteoporosis therapies that reduce
the risk of re-fracture through an FLS [28–30]. However, the
reduction in fracture risk from pharmacological therapies typ-
ically takes between 6 and 12 months of adherent therapy.
This has two important implications. Firstly, we need to en-
sure that those eligible for osteoporosis therapy are initiated as
early as possible after fracture and are monitored for short- and
long-term adherence to therapy. This is captured by FLS
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standards developed by the International Osteoporosis Foun-
dation [31]. Secondly, further evidence is needed to inform
which specific rehabilitation-based interventions can reduce
this early re-fracture risk after the index hip fracture. Given
that a significant proportion of patients present with cognitive
impairment, further research is needed to identify the most
effective and cost-effective rehabilitation pathways for these
patients [6].
It is also important to consider the impact of hip fracture on
mortality.We found this to be high in our patient cohort during
the first year post-fracture (9.4 % at 30 days and 31.2 % at
1 year) and similar to previous UK studies where mortality
ranged from 4.5 to 11.5 % at 30 days and 28.7 to 33 % at
1 year [32, 33]. Furthermore, a recent systematic review re-
ported the excess mortality in the hip fracture population to be
at least double of what was reported for age-matched general
populations [32]. Hence, designing and implementing cost-
effective management pathways and strategies focusing on
reducing the risk of (re)fracture may not only result in poten-
tial healthcare cost-savings from preventing fracture(s) but
also in life-expectancy gains. Finally, we found mortality to
be different between male and female patients both at 30 days
and at 1 year post-fracture. Again, this was consistent with
previous work where male patients were reported to have at
least twice the risk of death compared to female patients [32].
However, further research is required to examine the contri-
bution of co-morbidities and other risk factors both in terms of
excess mortality compared to the general population and gen-
der differences.
In addition to the above, we recognise the following limi-
tations. The hospital data were confined to a single region in
the UK. However, this region has a representative rate of hip
fracture cases with similar gender and age distribution as the
rest of the UK [21]. Furthermore, the length of stay of index
admission of a hip fracture is similar to that reported across the
UK (19 vs. 20 days in 2012) [21] and, by capturing actual
NHS activity, our results are strongly generalizable. Although
datasets such as HES capture key variables influencing costs
of hospital stay such as diagnosis and procedures during epi-
sodes of hospitalisation, they are not comprehensive in record-
ing other morbidity and severity measures. Nonetheless, the
validity of the HES dataset in identifying hip fracture cases
has been shown to be very high [21]. Furthermore, the ascer-
tainment of diagnosis and co-morbidities occurs mostly in
patients with admitted patient care (inpatient stay or day
cases), and a better understanding is required of the reasons
for outpatient and emergency contacts. Also, it would have
been useful to have linked hospital data with primary, com-
munity and social care records and estimate the costs beyond
the hospital setting. This is, however, very limited with the
current administrative datasets in the UK. Nonetheless, an
approximation of the care home costs was possible. We esti-
mated the average cost of a stay in a care home to be £26,203
for those patients admitted to one (24.4 % of whole cohort,
with a mean of 245 days in care home at the cost of £750 per
week). Hence, across all hip fracture cases, the care home
costs would have averaged £6299 per patient, which would
have increased the total costs of hip fracture to £20,563 in the
first year and accounted for almost a third of total costs.
Hence, despite these limitations, the quality of the dataset
and the large sample size allowed us to make robust estimates
of the hospital costs of hip fracture and the impact of patient
characteristics such as age, gender and income deprivation
and hip fracture-related complications.
In conclusion, our results show the impact of the first and
second hip fracture on hospital costs and its predictors in the
UK. Our results highlight the impact of complications follow-
ing initial hospital discharge as a main driver of costs and the
importance of preventing hip re-fractures. This study will be
useful to commissioners, providers and researchers estimating
the long-term cost-effectiveness of interventions for the pre-
vention and management of these conditions such as an FLS.
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